Lumibird SA

Paris Stock Exchange LBIRD.PA

Lumibird SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 23.94 M

Lumibird SA Net Cash Used Provided By Financing Activities is USD 23.94 M for the year ending December 31, 2023, a 383.59% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Lumibird SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -8.44 M, a -140.74% change year over year.
Lumibird SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 20.72 M, a -79.98% change year over year.
Lumibird SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 103.54 M, a 218.98% change year over year.
Lumibird SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 32.46 M, a 183.95% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Paris Stock Exchange: LBIRD.PA

Lumibird SA

CEO	Dr. Marc Le Flohic
IPO Date	April 12, 2000
Location	France
Headquarters	2 rue Paul Sabatier
Employees	1,053
Sector	Health Care
Industries Pharmaceuticals Aerospace Semiconductors

Description

Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment. The company was founded in 1970 and is headquartered in Lannion, France.

Key trends

Past 5 years